Skip to main content
Premium Trial:

Request an Annual Quote

PE Says Affymetrix Infringes on Patents

Premium

PE Biosytems filed a law suit alleging that Affymetrix’s products infringe on five PE patented inventions.

In the lawsuit, filed in the US District Court in Delaware, PE alleged that Affymetrix “has long been aware of the patents” but nevertheless continued to make and sell its GeneChip Probe Array.

According to court papers, the alleged infringement concerns patents used to synthesize oligonucleotides and to speed up production of DNA.

In response, Vern Norviel, general counsel of Affymetrix said: “Affymetrix purchases its reagents from licensed vendors, therefore, we believe we have meritorious defenses to the claims in this lawsuit.”

PE of Norwalk, Conn., asked the court to block Affymetrix from further alleged infringement and to award unspecified damages.

Based in Santa Clara, Calif., Affymetrix’s gene chip technology allow researchers to analyze and manage genetic information. Glaxo Wellcome owns 22 percent of Affymetrix.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.